학술논문
Facing real-life with direct oral anticoagulants in patients with nonvalvular atrial fibrillation: outcomes from the first observational and prospective study in a Spanish population
Document Type
Article
Author
Source
Journal of Comparative Effectiveness Research; February 2018, Vol. 8 Issue: 3 p165-178, 14p
Subject
Language
ISSN
20426305; 20426313
Abstract
Aim:To analyze the effectiveness and safety of direct oral anticoagulants (DOACs) in atrial fibrillation (AF) patients attended in clinical practice. Methods:Observational and prospective study of AF patients that started treatment with DOACs. Results:1443 patients (age 77.2 ± 9.7 years, CHA2DS2-VASc 4.1 ± 1.5) were included. 46.0 were taking rivaroxaban, 24.4 dabigatran, 22.5 apixaban and 7.1 edoxaban. Patients taking dabigatran were younger, had lower CHA2DS2-VASc and lesser renal insufficiency. Patients taking apixaban had higher CHA2DS2-VASc and more renal insufficiency. Rates of stroke/major bleeding/intracranial bleeding were 0.7/1.3/0.2 events/100 patient-years, respectively. Conclusion:This was the first prospective study that analyzed the use of all DOACs in AF patients in Spain, showing a good profile in terms of safety and effectiveness in accordance with pivotal studies.